CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: In vitro comparison to mifepristone and CDB-2914

Molecular and Cellular Endocrinology

Volumn 188, Issue 1-2, 2002, Pages 111-123

  Attardi, Barbara J ^a   Burgenson, Janet ^a   Hild, Sheri A ^a   Reel, Jerry R ^a   Blye, Richard P ^b  

^a BIOQUAL INC   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

(HepG2 cells); (T47D CO cells); Alkaline phosphatase; Glucocorticoid receptor; Progestin receptor; Transactivation

Indexed keywords

17ALPHA ACETOXY 11BETA (4 DIMETHYLAMINOPHENYL) 19 NORPREGNA 4,9 DIENE 3,20 DIONE; 17ALPHA ACETOXY 11BETA (4 DIMETHYLAMINOPHENYL) 21 METHOXY 19 NORPREGNA 4,9 DIENE 3,20 DIONE; 17ALPHA ACETOXY 11BETA [4 N,N DIMETHYLAMINOPHENYL] 19 NORPREGNA 4,9 DIENE 3,20 DIONE; 17ALPHA ACETOXY 21 METHOXY 11BETA [4 N METHYLAMINOPHENYL] 19 NORPREGNA 4,9 DIENE 3,20 DIONE; 17ALPHA ACETOXY 21 METHOXY 11BETA [4 N,N DIMETHYLAMINOPHENYL] 19 NORPREGNA 4,9 DIENE 3,20 DIONE; 8 BROMO CYCLIC AMP; ALKALINE PHOSPHATASE; ANTIGESTAGEN; CDB 4453; DRUG METABOLITE; GLUCOCORTICOID ANTAGONIST; GLUCOCORTICOID RECEPTOR; LUCIFERASE; MIFEPRISTONE; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR; PROMEGESTONE; RECEPTOR SUBUNIT; RECOMBINANT RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG ACTIVITY; DRUG POTENCY; ENZYME ANALYSIS; ENZYME INDUCTION; ENZYME SYNTHESIS; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PLASMID; PREDICTION; PRIORITY JOURNAL; RECEPTOR BINDING; THYMUS; TRANSACTIVATION;

EID: 0037169814     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(01)00743-2     Document Type: Article

References (36)

1. RU486: Pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri
2. Transcriptional regulation of the glycoprotein hormone α-subunit gene by pituitary adenylate cyclase-activating polypeptide (PACAP) in αT3-1 cells
3. The progesterone antagonist RU 486 acquires agonist activity upon stimulation of cAMP signaling pathways
4. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
5. Antagonist effect of RU486 on transcription of glucocorticoid-regulated genes
6. RU486 (MIFEPRISTONE): Mechanisms of action and clinical uses
7. Characterization and functional properties of the A and B forms of human progesterone receptors synthesized in a baculovirus system
8. Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist
9. Analysis of the relation between receptor binding affinity and antagonist efficacy of antiglucocorticoids
10. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding
11. New antiprogestins with partial agonist activity: Potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties
12. CDB-2914: Anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits
13. The antiprogestin RU38 486: Receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47D-CO human breast cancer cells
14. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT
15. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer
16. Screening of antiprogestagens by receptor studies and bioassays
17. The rabbit progesterone receptor. Evidence for a single steroid-binding subunit and characterization of receptor mRNA
18. Estrogenic and progestagenic activities coexisting in steroidal drugs: Quantitative evaluation by in vitro bioassays with human cells
19. Effect of local application of progesterone on the rabbit uterus
20. The assay of progestin
21. Modulation of cell signaling pathways can enhance or impair glucocorticoid-induced gene expression without altering the state of receptor phosphorylation
22. New steroids with antiprogestational and antiglucocorticoid activities
23. Latent agonist activity of the steroid antagonist, RU486, is unmasked in cells treated with activators of protein kinase A
24. The coupling of multiple signal transduction pathways with steroid response mechanisms
25. Mechanism of action of an antiprogesterone, RU486, in the rabbit endometrium: Effects of RU486 on the progesterone receptor and on expression of the uteroglobin gene
26. Antiovulatory and postcoital antifertility activity of the antiprogestin CDB-2914 when administered as single, multiple, or continuous doses to rats
27. Biological potencies of chemically modified andrenocorticosteroids in rats and man
28. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP
29. 50 values of several synthetic (anti)progestagens in vitro in CHO and MCF-7 cells and in vivo in rabbits and rats
30. Reversible suppression of menstruation with progesterone antagonists in rhesus macaques
31. Progesterone receptor modulators and progesterone antagonists in women's health
32. Antiprogestins: Mechanism of action and contraceptive potential
33. History and perspectives of antiprogestins from the chemist's point of view
34. Activation of pRL-TK by 12S E1A oncoprotein: Drawbacks of using an internal reference reporter in transcription assays
35. The nuclear corepressors NcoR and SMRT are key regulators of both ligand and 8-Bromo-cAMP dependent transcriptional activity of the human progesterone receptor
36. The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: Implications for the development of dissociated antiprogestins